EC145 shows anti-tumor activity in ovarian cancer
BELGRADE-Endocyte presented phase IIa data from its trial using EC145 (pegylated liposomal doxorubicin) in women with advanced-stage ovarian cancer at the 2009 European Society of Gynaecological Oncology.
BELGRADE-Endocyte presented phase IIa data from its trial using EC145 (pegylated liposomal doxorubicin) in women with advanced-stage ovarian cancer at the 2009 European Society of Gynaecological Oncology. The study participants had a median of four prior exposures to chemotherapy and 88% were diagnosed with having a tumor volume of greater than 5 cm in diameter. The overall disease control rate, defined as stable disease or partial or complete response to therapy, was 40.8% (abstract 1181).
Based on these results, the trial will move into phase IIb, a randomized study of EC145 in combination with doxorubicin HCl (Doxil/Caelyx ) vs doxorubicin HCl alone in women with platinum-resistant ovarian cancer.
